GLP-1s are driving returns on R&D investments for Big Pharma, report says
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff (Getty Images) Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic. Deloitte’s annual report, Measuring the Return from Pharmaceutical Innovation, found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the...